Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL6 | Q9H5J4 | 18/20 | 1.00 |
| ▸ | ELOVL3 | Q9HB03 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.90 |
| ▸ | MAPT | P10636 | 1/20 | 0.87 |
| ▸ | HTT | P42858 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL486551 | 1.00 | ELOVL6 (1.00) | ELOVL6ELOVL3MEN1KMT2AMAPT | |
| SCHEMBL486051 | 0.95 | ELOVL6 (1.00) | ELOVL6ELOVL3MEN1KMT2AMAPT | |
| SCHEMBL486548 | 0.94 | ELOVL6 (1.00) | ELOVL6ELOVL3MEN1KMT2AMAPT | |
| SCHEMBL486223 | 0.93 | ELOVL6 (1.00) | ELOVL6ELOVL3MEN1KMT2AMAPT | |
| SCHEMBL486132 | 0.93 | ELOVL6 (0.92) | ELOVL6ELOVL3MEN1KMT2AMAPT | |
| SCHEMBL486655 | 0.93 | ELOVL6 (1.00) | ELOVL6ELOVL3MEN1KMT2AMAPT | |
| SCHEMBL486406 | 0.92 | ELOVL6 (0.91) | ELOVL6ELOVL3MEN1KMT2AMAPT | |
| SCHEMBL486064 | 0.92 | ELOVL6 (1.00) | ELOVL6ELOVL3MEN1KMT2AMAPT | |
| SCHEMBL486256 | 0.92 | ELOVL6 (0.91) | ELOVL6ELOVL3MEN1KMT2AMAPT | |
| SCHEMBL486253 | 0.92 | ELOVL6 (1.00) | ELOVL6ELOVL3MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106086-B2 | Indoledione derivative | MSD K.K. (JP) | 2012-01-31 | — | — | US | claimed |
| US-20100056597-A1 | INDOLEDIONE DERIVATIVE | MSD K.K. (JP) | 2010-03-04 | — | — | US | claimed |
| EP-2145884-A1 | INDOLEDIONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-01-20 | — | — | EP | claimed |
| EP-2145884-B1 | INDOLEDIONE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-8106086-B2 | Indoledione derivative | MSD K.K. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20100056597-A1 | INDOLEDIONE DERIVATIVE | MSD K.K. (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2145884-A1 | INDOLEDIONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056597-A1 | INDOLEDIONE DERIVATIVE | LIPE, IDO1, ADRA1A | ELOVL6 1113/4885ELOVL3 1420/4885MEN1 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.